Global brokerage UBS has initiated coverage on Shaily Engineering Plastics, India’s leading exporter of high-precision engineered plastic components, with a ‘Buy’ rating and a target price of ₹4,000, indicating a potential upside of 60% from the current market price. UBS highlighted Shaily’s unique patented technology for fixed-dose and auto-injector pens, positioning it strongly for the upcoming launch of generic GLP-1 therapies. With the GLP-1 (semaglutide) patent expiring in 2026 across India, Canada, and Brazil, UBS estimates a combined market of 550–600 million devices, translating to ₹80–85 billion in revenue by 2030.
Shaily has already secured 23–24 clients for the GLP-1 launch, supporting UBS’s projection of a 96% revenue CAGR for its healthcare segment between FY25–28. High entry barriers, patented technology, regulatory approvals, and limited global manufacturing capacity make Shaily a critical supplier in the pharmaceutical supply chain. Additional opportunities include a major client in consumer electronics and benefits from potential India-US trade deals. UBS expects the company to achieve a 75% EPS CAGR over FY25–28. The stock has been a stellar performer, rising 700% over two years and delivering extraordinary long-term returns of over 25,000% in 11 years, reflecting its wealth-creating potential on Dalal Street.